Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New model could predict deadly liver failure after surgery

NCT ID NCT06366048

Knowledge-focused Sponsor: National Natural Science Foundation of China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the amount of healthy liver removed during surgery can predict liver failure afterward. Researchers will create a risk model based on 1,600 patients who had liver surgery for cancer. The goal is to help doctors identify high-risk patients before surgery and improve safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give surgeons a simple tool to predict which patients are at high risk of liver failure after surgery, helping them plan safer operations.
What could go wrong
This is an observational study, not a treatment trial. The model may not be accurate for all patients or hospitals, and it does not test any new drug or therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1133 consecutive patients diagnosed with hepatocellular carcinoma (HCC) and intracholangiocarcinoma underwent hepatectomies.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * selective hepatectomies; * histologically confirmed as HCC and ICC * complete and accessible data Exclusion criteria: * any history of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) * any history of portal vein embolism (PVE) * any history of tumor rupture * emergency surgery * pathologically diagnosed with neither HCC nor ICC * concomitant resection of gastrointestinal organs, spleenectomy or other organs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma intrahepatic cholangiocarcinoma liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Mengchao Hepatobiliary Hospital of Fujian Medical University

    RECRUITING

    Shenzhencun, Shanghai Municipality, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    RECRUITING

    Fujian, Shanghai Municipality, China

  • The Third Affiliated Hospital of Naval Medical University

    RECRUITING

    Shanhai, Shanghai Municipality, 201800, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.